GLAUKOS Corp Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
GLAUKOS Corp (GKOS) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $2.16 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-02-23
- GLAUKOS Corp effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2024 was $2.16M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2024-12-31 | $2.16M 10-K · filed 2026-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| HAEMONETICS CORP (HAE) | United States | $4.821B | 36.52 |
| Heartflow, Inc. (HTFL) | United States | $4.225B | |
| ICU MEDICAL INC/DE (ICUI) | United States | $4.153B | 18.85 |